PROGRAMME AT A GLANCE Time (CET) Wednesday, 5 May 2021 Thursday 6 May 2021 Friday 7 May 2021 09:30-14:30 Side meetings: 09:30-11:00 EATG multi-level stakeholder meeting regarding Plenary/abstract-driven session: COVID-19’s diagnostics impact on prevention and testing services for Plenary/abstract-driven session: Implementing 13:00-14:15 11:30-13:00 Lisbon Fast Track HIV, viral hepatitis, STIs and TB: Building back integrated testing strategies Cities better 13:30-14:30 IAPAC/European Fast Track Cities Abstract driven session: The use of new Abstract driven session: Models of testing and 14:30-15:30 technologies to increase testing coverage linkage to care for PWID and PWUD 15:00-17:00 Opening session E-poster sessions (live Q&A) and E-exhibitions E-poster sessions (live Q&A) and E-exhibitions 15:30-16:30 (Break) (Break) Plenary/abstract-driven session: Combination Plenary session: Special Session on people who 16:30-17:45 prevention in HIV, viral hepatitis, STIs and TB inject/use drugs (EMCDDA/ECDC) Closing session: A new health model toward an 18:00-19:00 INTEGRATE session (format and timing TBD) integrated continuum of care 1 Wednesday, 5 May 2021 Time (CET) Side meetings 09:30-11:00 EATG multi-level stakeholder meeting regarding diagnostics 11:30-13:00 Lisbon Fast Track Cities 13:30-14:30 IAPAC Fast Track Cities Time (CET) Presen Session Moderators and speakers tation No. 15:00-17:00 OS OPENING SESSION Moderators: Daniel Simões and Jürgen Rockstroh 15:00-15:10 OS/01 Welcome: Conference objectives and overview Conference chairs: Ricardo Baptista Leite (Local co-chair), Daniel Simões, Jürgen Rockstroh (Conference chairs) 15:10-15:20 OS/02 Welcome message from the Portuguese Minister of Health Portuguese Minister of Health Marta Temido (TBC) 15:20-15:30 OS/03 Welcome from the European Commission: The EU response on HIV, viral hepatitis, STIs and TB in the future John Ryan, Director of Public Health, DG Sante (TBC) 15:30-15:40 OS/04 Post-2020/COVID-19 and progress towards the SDG targets: Where are we? Andrea Ammon, Director, European Centre for Disease Prevention and Control (ECDC) 15:40-15:50 OS/05 ‘The changed landscape’ – providing testing for HIV/STIs/hepatitis/TB in the era of COVID-19 Hans Kluge, Regional Director, WHO Regional Office for Europe 15:50-16:00 OS/O6 Country Spotlight: Portugal’s progress in reaching the global targets and interventions for integration of testing Rep. from National Directorate of the Portuguese Ministry (TBC) 16:00-16:10 OS/07 Community perspective on enabling environments for integrated testing and linkage to care across Europe Daniel Simões, GAT Portugal 16:10-17:00 Panel discussion 2 Thursday, 6 May 2021 Time (CET) Session Moderators and speakers PLENARY/ABSTRACT DRIVEN SESSION 1: SPECIAL SESSION: COVID-19’s impact on prevention and testing services for HIV, Moderators: TBD 13:00-14:15 PS1 viral hepatitis, STIs and TB: Building back better Overview of the impact of COVID-19 on progress toward the SDG targets Anthony Fauci, Director, NIAID, USA 13:00-13:10 PS1/01 (TBC) A.R. Stengaard1, A. Sullivan2, J.D Kowalska3, C. Rokx4, D. Raben1, D. Impact of the COVID-19 pandemic on linkage to and retention in care for HIV, hepatitis B and C and sexually transmitted 13:10-13:20 PS1/02 Simões5, The EuroTEST COVID-19 infections in the WHO European Region impact assessment consortium of partners [Abstract 35] A. Schafberger1, K.M. Dymek2, G. s.a.m Health: Germany’s first digital sexual health service is providing COVID-safe remote STI testing and counselling during the 13:20-13:30 PS1/03 Waltinger3, G. Davies4, C. Kantwerk1 Covid-19 Pandemic and beyond [Abstract 61] V. Evseeva1, M. Greysman1, V. Rapid HIV testing and linkage in rehabilitation centers during COVID-19 pandemics, Yekaterinburg and Sverdlovsk region, Stanilevskiy2, N. Mironova2, A. 13:30-13:40 PS1/04 Russia Chuykov3, A.M. Żakowicz3 [Abstract 71] B. Collins1, C. Bom Kahama2, D. 13:40-13:50 PS1/05 European testing week: adaptation of testing services during the COVID-19 pandemic Raben2 [Abstract 58] 13:50-14:15 Discussion 14:15-14:30 Break 14:30-15:30 AS1 ABSTRACT DRIVEN SESSION 1: The use of new technologies to increase testing coverage Moderators: TBD L. Cosmaro1, D. Savarino1, M. Mommi2, Z. Dominkovic3, A. Simkunaite-Zazecke4, L. Stoniene5, A. 14:30-14:37 AS1/01 RiskRadar: the 1st integrated ICT tool on combination prevention for hepatitis/HIV/TB/STI Raahauge6, C. Kakalou7, V. Drosou8, P. Natsiavas7 [Abstract 39] J. Taylor1,2, G. Holdsworth1, S. Amos- An evaluation of the outcomes of an online HIV self-sampling service to inform risk communication and future online testing 14:37-14:44 AS1/02 Gibbs1, E. Ardines1, B. George1, J. policy Harbottle1, P. Baraitser1,3 [Abstract 33] 3 C. Agustí1,2, O. Cunillera3, J. Almeda3, Efficacy of an on-screen computer reminder for HIV screening in primary care based on indicator conditions: a cluster J. Mascort4,5, R. Carrillo4,5, C. Olmos3, J. 14:44-14:51 AS1/03 randomized controlled trial Casabona1,2 [Abstract 23] A. Basu1, B. George1, G. Holdsworth1 14:51-14:58 AS1/04 Breaking the Chain? A once in a generation opportunity to find and treat HIV during UK’s COVID-19 lockdown [Abstract 40] 14:58-15:30 Discussion E-poster sessions (live Q&A) and E-exhibitions (Break) E-poster Sessions (live Q&A): 15:30-16:30 PO1: Innovative testing services during the COVID-19 pandemic: lessons learned PO2: Impact of COVID-19 on provision of services for people who inject/use drugs PO3: New testing technologies to increase testing coverage: HIV self-testing and home-based sampling 16:30-17:45 PS2 PLENARY/ABSTRACT DRIVEN SESSION 2: Combination prevention in HIV, viral hepatitis, STIs and TB Moderators: TBD Claudia Estcourt, Glasgow Caledonian 16:30-16:40 PS2/01 “Prevention is hard, Combination is key” – Good example of HIV/STI combination prevention in Scotland University Patrick Hoffmann, Luxembourg 16:40-16:50 PS2/02 Combination disease prevention in prisons: a comprehensive programme in Luxembourg Directorate of Health 16:50-17:00 PS2/03 Good example of TB combination prevention in Netherlands Gerard de Vries, RIVM E. Smout1, J. Williams2, A. Miners2, K. Phyu3, L Parker3, A Evans3, J McLaren3, The ‘Get Tested LeEDs’ project: clinical impact and cost-effectiveness of opt-out emergency department testing for 17:00-17:10 PS2/04 M. Aldersley3, G. Hughes1, M. Ruf4, E. bloodborne viruses (BBVs) in England Page3 [Abstract 78] 17:10-17:45 Discussion 17:45-18:00 Break 18:00-19:00 INTEGRATE SESSION Moderators: TBD 4 Friday, 7 May 2021 Time (CET) Session Moderators and Speakers 13:00-14:15 PS3 PLENARY SESSION 3: Implementing integrated testing strategies Moderators: TBD 13:00-13:10 Short report from Conference Day 1 Conference chairs Raimonda Matulionytė, Vilnius 13:10-13:20 PS3/01 Experiences in innovative testing approaches for HIV, hepatitis, STIs and TB University Hospital Santaros Klinikos Amiran Gamkrelidze, National Center 13:20-13:30 PS3/02 Integrated screening for TB, HIV and HCV at the primary healthcare level for Disease Control and Public Health, Georgia M. Gogishvili1, L. Fernàndez López1,2,3, Evolution of key indicators for community-based voluntary counseling and testing activity in Europe: COBATEST Network 13:30-13:40 PS3/04 J. Casabona Barbarà1,2,3 2017-2019 [Abstract 54] 13:40-13:50 PS3/05 Implementing self-test programmes during COVID-19 Robert Hejzak, Czech AIDS Help Society 13:50-14:15 Discussion 14:15-14:30 Break 14:30-15:30 AS2 ABSTRACT DRIVEN SESSION 2: Models of testing and linkage to care for PWID and PWUD Moderators: TBD S. Ciobanu1, A. Bocai1, M. Dan1, A. Testing and linkage to care services for 1000 people who inject drugs from Bucharest through the implementation of a three 14:30-14:37 AS2/01 Luca1, R. Teodorescu1 level HCV elimination strategy [Abstract 14] S. Shirley-Beavan1, R. Csak1, C. Daniels1, N. Burke-Shyne1, G. Lasco2, 14:37-14:44 AS2/02 Integrated harm reduction responses to HIV and viral hepatitis in the COVID-19 pandemic: a global overview M. Platko3, J. di Iorio4, C. Ahumada4, S. Hajal5, E. Aaraj5, C. Baguma6, K. Naik7 [Abstract 13] S. Mazzilli1,2, T. Sebastiani3, V. Casigliani1, G. Cocca3, A. Stemat3, C. 14:44-14:51 AS2/03 Feasibility of HCV micro-elimination: HCV test and treatment in two harm reduction services in Milan, Italy Nicola3, C. Selva3, C. Catani3, L. Tavoschi1, R. Ranieri3 [Abstract 32] E. Emanuel1, S. Croxford1, E. Phipps1, A. Ibitoye1, J. Njoroge1, C. 14:51-14:58 AS2/04 Blood-borne virus testing in people who inject drugs with a history of sex work Edmundson1, L. Slater1 [Abstract 27] 5 R. Rigoni1, T. Tammi2, E. Schatz1 14:58-15:05 AS2/05 HCV care for PWID in Europe - results from a civil society-led monitoring [Abstract 31] 15:05-15:30 Discussion Discussion E-poster Sessions and Exhibition area (break) E-poster Sessions (live Q&A): 15:30-16:30 PO4: Integrated testing programmes for hepatitis/HIV/TB/STI: health care settings PO5: Integrated testing programmes for hepatitis/HIV/TB/STI: community-based settings PO6: Models of testing and linkage to care for people who inject/use drugs 16:30- 17:45 PS4 PLENARY SESSION 4: SPECIAL SESSION: People who inject/use drugs (EMCDDA/ECDC) Moderators: Anne Bergenström (EMCDDA) and Viktor Mravčík (Head of the National Monitoring Centre for Drugs and Addictions, Czechia) 16:30-16:40 PS4/01 Keeping the HIV/Hepatitis targets for PWID on track during the Covid-19 pandemic: a European perspective Thomas Seyler, EMCDDA 16:40-16:50 PS4/02 New evidence on testing and linkage to care for PWIDs Otilia Mardh, ECDC 16:50-17:00 PS4/03 Ensuring